| | | | | | | | | | | | | | | | |
| | |
 | Issue Date FY: 2026 ( Subtotal = $4,829,770 ) (Continued on the next page) |
| | 2026 | 2026 | UNIVERSITY OF OKLAHOMA | 865 RESEARCH PKWY | OKLAHOMA CITY | OK | 73104-3609 | OKLAHOMA | USA | T9952111 | Value-Based Medical Student Education Training Program | 01 | 3 | HRSA | 12/9/2025 | $49,281 |
| | 2026 | 2026 | UNIVERSITY OF OKLAHOMA | 865 RESEARCH PKWY | OKLAHOMA CITY | OK | 73104-3609 | OKLAHOMA | USA | R01HD110585 | Preconception Maternal Nutrition, Offspring DNA Methylation, and InfantGrowth in Low Resource Settings | 000 | 3 | NIH | 1/31/2026 | $420,979 |
| | 2026 | 2026 | UNIVERSITY OF OKLAHOMA | 865 RESEARCH PKWY | OKLAHOMA CITY | OK | 73104-3609 | OKLAHOMA | USA | R01DK134316 | Novel Roles of Cullin-RING E3 Ligases in Liver Pathophysiology | 000 | 4 | NIH | 1/30/2026 | $392,869 |
| | 2026 | 2026 | UNIVERSITY OF OKLAHOMA | 865 RESEARCH PKWY | OKLAHOMA CITY | OK | 73104-3609 | OKLAHOMA | USA | UG1CA287044 | Oklahoma TRUST Access Hub | 000 | 3 | NIH | 1/30/2026 | $732,478 |
| | 2026 | 2026 | UNIVERSITY OF OKLAHOMA | 865 RESEARCH PKWY | OKLAHOMA CITY | OK | 73104-3609 | OKLAHOMA | USA | F31AI189149 | Human gut Bacteroidales defense mechanisms against emerging antibacterial toxins | 000 | 2 | NIH | 12/29/2025 | $46,966 |
| | 2026 | 2026 | UNIVERSITY OF OKLAHOMA | 865 RESEARCH PKWY | OKLAHOMA CITY | OK | 73104-3609 | OKLAHOMA | USA | F31DK146691 | Role of interferon gamma in injury accelerated cystic kidney disease | 001 | 1 | NIH | 12/19/2025 | $0 |
| | 2026 | 2026 | UNIVERSITY OF OKLAHOMA | 865 RESEARCH PKWY | OKLAHOMA CITY | OK | 73104-3609 | OKLAHOMA | USA | R00GM141267 | Identification of novel osmosensing receptors in C. elegans | 000 | 5 | NIH | 1/9/2026 | $224,100 |
| | 2026 | 2026 | UNIVERSITY OF OKLAHOMA | 865 RESEARCH PKWY | OKLAHOMA CITY | OK | 73104-3609 | OKLAHOMA | USA | R01HD109784 | Prevention of Necrotizing Enterocolitis | 000 | 4 | NIH | 1/14/2026 | $368,415 |
| | 2026 | 2026 | UNIVERSITY OF OKLAHOMA | 865 RESEARCH PKWY | OKLAHOMA CITY | OK | 73104-3609 | OKLAHOMA | USA | R01CA297076 | Protein-nanoparticle interaction to study multicellular crosstalk within ovarian tumor microenviroment | 000 | 2 | NIH | 1/19/2026 | $293,492 |
| | 2026 | 2026 | UNIVERSITY OF OKLAHOMA | 865 RESEARCH PKWY | OKLAHOMA CITY | OK | 73104-3609 | OKLAHOMA | USA | R01DK133207 | ROCK, tight junctions and prematurity in the pathogenesis of necrotizing enterocolitis and neonatal sepsis. | 000 | 4 | NIH | 1/19/2026 | $480,675 |
| | 2026 | 2026 | UNIVERSITY OF OKLAHOMA | 865 RESEARCH PKWY | OKLAHOMA CITY | OK | 73104-3609 | OKLAHOMA | USA | R01CA298165 | A Randomized Factorial Trial of Varenicline with Nicotine Lozenges and a Smartphone Medication Adherence Intervention to Promote Smoking Cessation | 000 | 2 | NIH | 12/17/2025 | $546,679 |
| | 2026 | 2026 | UNIVERSITY OF OKLAHOMA | 865 RESEARCH PKWY | OKLAHOMA CITY | OK | 73104-3609 | OKLAHOMA | USA | F31DK146691 | Role of interferon gamma in injury accelerated cystic kidney disease | 000 | 1 | NIH | 12/19/2025 | $41,422 |
| | 2026 | 2026 | UNIVERSITY OF OKLAHOMA | 865 RESEARCH PKWY | OKLAHOMA CITY | OK | 73104-3609 | OKLAHOMA | USA | T9952111 | Value-Based Medical Student Education Training Program | 01 | 3 | HRSA | 12/9/2025 | $255,758 |
| | 2026 | 2026 | UNIVERSITY OF OKLAHOMA | 865 RESEARCH PKWY | OKLAHOMA CITY | OK | 73104-3609 | OKLAHOMA | USA | T9952111 | Value-Based Medical Student Education Training Program | 01 | 3 | HRSA | 12/9/2025 | $11,973 |
| | 2026 | 2026 | UNIVERSITY OF OKLAHOMA | 865 RESEARCH PKWY | OKLAHOMA CITY | OK | 73104-3609 | OKLAHOMA | USA | T9952111 | Value-Based Medical Student Education Training Program | 01 | 3 | HRSA | 12/9/2025 | $857,988 |
| | 2026 | 2026 | UNIVERSITY OF OKLAHOMA | 865 RESEARCH PKWY | OKLAHOMA CITY | OK | 73104-3609 | OKLAHOMA | USA | R01CA260449 | Exploiting gold nanoparticle as a probe to identify therapeutic targets | 000 | 5 | NIH | 12/4/2025 | $319,463 |
| | 2026 | 2026 | UNIVERSITY OF OKLAHOMA | 865 RESEARCH PKWY | OKLAHOMA CITY | OK | 73104-3609 | OKLAHOMA | USA | H7600185 | Ryan White Part C Outpatient EIS Program | 00 | 30 | HRSA | 12/29/2025 | $293,192 |
| | 2026 | 2025 | UNIVERSITY OF OKLAHOMA | 865 RESEARCH PKWY | OKLAHOMA CITY | OK | 73104-3609 | OKLAHOMA | USA | K01MD015295 | HealthyCells: A Culturally-Tailored Smoking Cessation Smartphone Intervention for African Americans with Adjunctive Treatment for Sedentary Behavior | 000 | 5 | NIH | 11/12/2025 | $0 |
| | 2026 | 2025 | UNIVERSITY OF OKLAHOMA | 865 RESEARCH PKWY | OKLAHOMA CITY | OK | 73104-3609 | OKLAHOMA | USA | R01DK129656 | Understanding the metabolic pathology of pediatric obesity and NAFLD | 000 | 4 | NIH | 12/9/2025 | $0 |
| | 2026 | 2025 | UNIVERSITY OF OKLAHOMA | 865 RESEARCH PKWY | OKLAHOMA CITY | OK | 73104-3609 | OKLAHOMA | USA | U1Q53063 | Geriatrics Workforce Enhancement Program | 02 | 2 | HRSA | 12/10/2025 | $0 |
| | 2026 | 2025 | UNIVERSITY OF OKLAHOMA | 865 RESEARCH PKWY | OKLAHOMA CITY | OK | 73104-3609 | OKLAHOMA | USA | R34DA060534 | Developing an Empowerment Theory-Based Smoking Cessation Intervention for People with High Levels of Social Stress | 000 | 2 | NIH | 12/5/2025 | -$222,227 |
| | 2026 | 2025 | UNIVERSITY OF OKLAHOMA | 865 RESEARCH PKWY | OKLAHOMA CITY | OK | 73104-3609 | OKLAHOMA | USA | F31DK137568 | Targeting kidney resident macrophage niche filling to slow cystic kidney disease | 000 | 2 | NIH | 2/5/2026 | -$10,556 |
| | 2026 | 2025 | UNIVERSITY OF OKLAHOMA | 865 RESEARCH PKWY | OKLAHOMA CITY | OK | 73104-3609 | OKLAHOMA | USA | R56EY037686 | Bacterial Cloaking Devices in Intraocular Infections | 000 | 1 | NIH | 1/27/2026 | $0 |
| | 2026 | 2025 | UNIVERSITY OF OKLAHOMA | 865 RESEARCH PKWY | OKLAHOMA CITY | OK | 73104-3609 | OKLAHOMA | USA | UG1CA233193 | A Lead Academic Participating Site in Oklahoma for the Design and Conduct of NCTN Clinical Trials | 001 | 6 | NIH | 1/22/2026 | $0 |
| | 2026 | 2025 | UNIVERSITY OF OKLAHOMA | 865 RESEARCH PKWY | OKLAHOMA CITY | OK | 73104-3609 | OKLAHOMA | USA | P30AG050911 | Oklahoma Nathan Shock Center of Excellence in Basic Biology of Aging | 000 | 11 | NIH | 12/31/2025 | $0 |
| | 2026 | 2025 | UNIVERSITY OF OKLAHOMA | 865 RESEARCH PKWY | OKLAHOMA CITY | OK | 73104-3609 | OKLAHOMA | USA | F30AG087705 | Regulation of Microglial Function by Major Histocompatibility Complex I in Aging and Alzheimer's Disease | 000 | 2 | NIH | 1/12/2026 | -$44,477 |
| | 2026 | 2025 | UNIVERSITY OF OKLAHOMA | 865 RESEARCH PKWY | OKLAHOMA CITY | OK | 73104-3609 | OKLAHOMA | USA | D8854923 | Postdoctoral Training in General, Pediatric and Public Health Dentistry and Dental Hygiene | 05 | 1 | HRSA | 1/8/2026 | $0 |
| | 2026 | 2025 | UNIVERSITY OF OKLAHOMA | 865 RESEARCH PKWY | OKLAHOMA CITY | OK | 73104-3609 | OKLAHOMA | USA | R01DA062632 | Addiction potential, flavoring content, and substitutability of concept flavored cigarillos | 000 | 1 | NIH | 1/15/2026 | $0 |
| | 2026 | 2025 | UNIVERSITY OF OKLAHOMA | 865 RESEARCH PKWY | OKLAHOMA CITY | OK | 73104-3609 | OKLAHOMA | USA | R01AI154274 | Cellular Mechanism of Oxysterol-Binding Protein (OSBP) in Viral Proliferation: A Chemical Biology Approach | 000 | 5 | NIH | 1/16/2026 | $0 |
| | 2026 | 2025 | UNIVERSITY OF OKLAHOMA | 865 RESEARCH PKWY | OKLAHOMA CITY | OK | 73104-3609 | OKLAHOMA | USA | H79SM085083 | Stronger Together: Attachment, Resilience, & Support (STARS): Helping Children and Youth Reach Their Full Potential | 001 | 3 | SAMHSA | 1/15/2026 | $0 |
| | 2026 | 2025 | UNIVERSITY OF OKLAHOMA | 865 RESEARCH PKWY | OKLAHOMA CITY | OK | 73104-3609 | OKLAHOMA | USA | H79SM085083 | Stronger Together: Attachment, Resilience, & Support (STARS): Helping Children and Youth Reach Their Full Potential | 000 | 3 | SAMHSA | 1/14/2026 | $0 |
| | 2026 | 2025 | UNIVERSITY OF OKLAHOMA | 865 RESEARCH PKWY | OKLAHOMA CITY | OK | 73104-3609 | OKLAHOMA | USA | F31AI179208 | Toxin B receptor mediated events in Clostridioides difficile disease | 000 | 2 | NIH | 12/4/2025 | -$23,401 |
| | 2026 | 2025 | UNIVERSITY OF OKLAHOMA | 865 RESEARCH PKWY | OKLAHOMA CITY | OK | 73104-3609 | OKLAHOMA | USA | UG3CA290310 | Discovery and Development of Natural Products for Interception of CRC | 000 | 2 | NIH | 11/26/2025 | $0 |
| | 2026 | 2025 | UNIVERSITY OF OKLAHOMA | 865 RESEARCH PKWY | OKLAHOMA CITY | OK | 73104-3609 | OKLAHOMA | USA | K23DA062104 | A translational evaluation of depressive symptomology and smoking cessation treatment mechanisms for just-in-time-adaptive-interventions | 000 | 1 | NIH | 12/4/2025 | $0 |
| | 2026 | 2025 | UNIVERSITY OF OKLAHOMA | 865 RESEARCH PKWY | OKLAHOMA CITY | OK | 73104-3609 | OKLAHOMA | USA | R01CA253391 | Normalizing aberrant metabolism in ovarian cancer by a unique drug delivery system | 000 | 5 | NIH | 11/13/2025 | $0 |
| | 2026 | 2025 | UNIVERSITY OF OKLAHOMA | 865 RESEARCH PKWY | OKLAHOMA CITY | OK | 73104-3609 | OKLAHOMA | USA | R01CA255840 | Chemotherapy-induced vascular cognitive impairment: role of endothelial senescence | 000 | 5 | NIH | 12/8/2025 | $0 |
| | 2026 | 2025 | UNIVERSITY OF OKLAHOMA | 865 RESEARCH PKWY | OKLAHOMA CITY | OK | 73104-3609 | OKLAHOMA | USA | R21EY035725 | Targeting Innate Inflammation Pathways to Treat Ocular Infections | 000 | 2 | NIH | 11/11/2025 | $0 |
| | 2026 | 2024 | UNIVERSITY OF OKLAHOMA | 865 RESEARCH PKWY | OKLAHOMA CITY | OK | 73104-3609 | OKLAHOMA | USA | R01EY031544 | Laser speckle flowgraphy as early indicator of microvasculopathy in radiation-induced vision loss | 002 | 6 | NIH | 1/23/2026 | -$316,351 |
| | 2026 | 2024 | UNIVERSITY OF OKLAHOMA | 865 RESEARCH PKWY | OKLAHOMA CITY | OK | 73104-3609 | OKLAHOMA | USA | R01EY031544 | Laser speckle flowgraphy as early indicator of microvasculopathy in radiation-induced vision loss | 001 | 6 | NIH | 1/23/2026 | $316,351 |
| | 2026 | 2024 | UNIVERSITY OF OKLAHOMA | 865 RESEARCH PKWY | OKLAHOMA CITY | OK | 73104-3609 | OKLAHOMA | USA | UG1CA233193 | A Lead Academic Participating Site in Oklahoma for the Design and Conduct of NCTN Clinical Trials | 000 | 6 | NIH | 1/21/2026 | $0 |
| | 2026 | 2024 | UNIVERSITY OF OKLAHOMA | 865 RESEARCH PKWY | OKLAHOMA CITY | OK | 73104-3609 | OKLAHOMA | USA | R01AG068283 | Tau-induced astrocyte senescence in Alzheimer's disease | 000 | 3 | NIH | 1/21/2026 | -$70,308 |
| | 2026 | 2024 | UNIVERSITY OF OKLAHOMA | 865 RESEARCH PKWY | OKLAHOMA CITY | OK | 73104-3609 | OKLAHOMA | USA | K99AG088478 | Non-invasive brain stimulation and neurovascular mechanisms of post-stroke cognitive impairment | 000 | 1 | NIH | 1/13/2026 | -$33,390 |
| | 2026 | 2024 | UNIVERSITY OF OKLAHOMA | 865 RESEARCH PKWY | OKLAHOMA CITY | OK | 73104-3609 | OKLAHOMA | USA | R01CA254192 | Exosomes as carriers of cancer therapeutics | 000 | 4 | NIH | 1/12/2026 | $0 |
| | 2026 | 2024 | UNIVERSITY OF OKLAHOMA | 865 RESEARCH PKWY | OKLAHOMA CITY | OK | 73104-3609 | OKLAHOMA | USA | R01CA281098 | Development of contrast agents to facilitate image-guided surgery | 000 | 2 | NIH | 1/20/2026 | $0 |
| | 2026 | 2024 | UNIVERSITY OF OKLAHOMA | 865 RESEARCH PKWY | OKLAHOMA CITY | OK | 73104-3609 | OKLAHOMA | USA | T9952111 | Value-Based Medical Student Education Training Program | 02 | 2 | HRSA | 11/19/2025 | $0 |
| | 2026 | 2023 | UNIVERSITY OF OKLAHOMA | 865 RESEARCH PKWY | OKLAHOMA CITY | OK | 73104-3609 | OKLAHOMA | USA | P20GM125528 | CELLULAR AND MOLECULAR GEROSCIENCE CoBRE | 000 | 5 | NIH | 1/26/2026 | $0 |
| | 2026 | 2023 | UNIVERSITY OF OKLAHOMA | 865 RESEARCH PKWY | OKLAHOMA CITY | OK | 73104-3609 | OKLAHOMA | USA | R21CA274072 | Study Pro-Oncogenic Role of BCL6 in CLL Tumorigenesis | 000 | 2 | NIH | 1/2/2026 | $0 |
| | 2026 | 2023 | UNIVERSITY OF OKLAHOMA | 865 RESEARCH PKWY | OKLAHOMA CITY | OK | 73104-3609 | OKLAHOMA | USA | R01CA163649 | Targeting MUC1-Mediated Tumor-Stromal Metabolic Cross-Talk in Pancreatic Cancer | 000 | 10 | NIH | 1/12/2026 | -$54,832 |
| | 2026 | 2023 | UNIVERSITY OF OKLAHOMA | 865 RESEARCH PKWY | OKLAHOMA CITY | OK | 73104-3609 | OKLAHOMA | USA | R01CA163649 | Targeting MUC1-Mediated Tumor-Stromal Metabolic Cross-Talk in Pancreatic Cancer | 000 | 10 | NIH | 1/12/2026 | -$6,813 |
|
